NASDAQ:MDGL

Madrigal Pharmaceuticals News Headlines

$117.02
+0.43 (+0.37 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$114.68
Now: $117.02
$117.37
50-Day Range
$112.08
MA: $117.70
$123.06
52-Week Range
$64.85
Now: $117.02
$137.28
Volume144,537 shs
Average Volume184,724 shs
Market Capitalization$1.88 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.19

Headlines

Madrigal Pharmaceuticals (NASDAQ MDGL) News Headlines Today

SourceHeadline
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $120.55Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $120.55
americanbankingnews.com - March 24 at 11:54 AM
MDGL Makes Notable Cross Below Critical Moving AverageMDGL Makes Notable Cross Below Critical Moving Average
nasdaq.com - March 23 at 5:42 PM
Madrigal Pharmaceuticals, Inc.(MDGL)Madrigal Pharmaceuticals, Inc.(MDGL)
fool.com - March 11 at 9:27 AM
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 25 at 7:22 AM
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 25 at 7:22 AM
The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomets Spin-Off, IPO Deluge Hits StreetThe Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street
msn.com - February 5 at 10:14 AM
Is MDGL A Good Stock To Buy Now?Is MDGL A Good Stock To Buy Now?
finance.yahoo.com - December 17 at 12:30 AM
Heres Why Were Not Too Worried About Madrigal Pharmaceuticals (NASDAQ:MDGL) Cash Burn SituationHere's Why We're Not Too Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
finance.yahoo.com - November 24 at 12:09 PM
MDGL Nov 2020 110.000 callMDGL Nov 2020 110.000 call
uk.finance.yahoo.com - November 21 at 8:03 PM
MDGL Nov 2020 80.000 callMDGL Nov 2020 80.000 call
uk.finance.yahoo.com - November 20 at 10:43 PM
MDGL Nov 2020 155.000 callMDGL Nov 2020 155.000 call
uk.finance.yahoo.com - November 20 at 5:41 PM
Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- SlideshowMadrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
seekingalpha.com - November 19 at 8:15 PM
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 TrialMadrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
finance.yahoo.com - November 13 at 10:06 AM
Madrigal completes patient enrollment for late-stage study of experimental NASH treatmentMadrigal completes patient enrollment for late-stage study of experimental NASH treatment
bizjournals.com - November 6 at 2:03 PM
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and HighlightsMadrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
finance.yahoo.com - November 5 at 8:54 AM
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American AssociationMadrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association
bloomberg.com - October 3 at 1:30 PM
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 TrialMadrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
marketwatch.com - September 3 at 8:10 AM
Madrigal Pharmaceuticals Exceeds Target Enrollment  in Phase 3 MAESTRO NAFLD-1 TrialMadrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
finance.yahoo.com - September 3 at 8:10 AM
Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream FadesIntercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream Fades
finance.yahoo.com - September 2 at 12:07 PM
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
finance.yahoo.com - August 26 at 8:37 AM
Notable Monday Option Activity: MDGL, IRBT, HGVNotable Monday Option Activity: MDGL, IRBT, HGV
nasdaq.com - August 17 at 4:43 PM
Madrigal Pharmaceuticals EPS misses by $0.74Madrigal Pharmaceuticals EPS misses by $0.74
seekingalpha.com - August 6 at 10:41 AM
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights
finance.yahoo.com - August 6 at 10:41 AM
Should You Avoid Madrigal Pharmaceuticals, Inc. (MDGL)?Should You Avoid Madrigal Pharmaceuticals, Inc. (MDGL)?
finance.yahoo.com - June 28 at 12:34 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. - MDGLSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. - MDGL
finance.yahoo.com - June 17 at 7:51 PM
Financials Madrigal PharmaceuticalsFinancials Madrigal Pharmaceuticals
markets.businessinsider.com - June 16 at 6:25 PM
We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business GrowthWe Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
finance.yahoo.com - May 28 at 10:04 AM
Was The Smart Money Right About Madrigal Pharmaceuticals (MDGL)?Was The Smart Money Right About Madrigal Pharmaceuticals (MDGL)?
finance.yahoo.com - May 10 at 3:40 PM
Madrigal Pharmaceuticals EPS misses by $0.40Madrigal Pharmaceuticals EPS misses by $0.40
seekingalpha.com - May 7 at 4:42 PM
Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights
finance.yahoo.com - May 7 at 4:42 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. - MDGLSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. - MDGL
finance.yahoo.com - May 5 at 6:01 PM
Barclays issues flurry of healthcare ratings in premarket analyst actionBarclays issues flurry of healthcare ratings in premarket analyst action
seekingalpha.com - May 5 at 8:08 AM
Madrigals Positive Data, And Other News: The Good, Bad And Ugly Of BiopharmaMadrigal's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - April 19 at 7:26 AM
Madrigal Pharmaceuticals Inc.Madrigal Pharmaceuticals Inc.
www.barrons.com - April 18 at 7:55 PM
Noteworthy Tuesday Option Activity: MDGL, DKS, EXPENoteworthy Tuesday Option Activity: MDGL, DKS, EXPE
www.nasdaq.com - April 14 at 7:35 PM
Madrigal Pharma up 13% on positive data on NASH drug resmetiromMadrigal Pharma up 13% on positive data on NASH drug resmetirom
seekingalpha.com - April 14 at 9:34 AM
Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis ReductionMadrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction
finance.yahoo.com - April 14 at 9:34 AM
Madrigal: A Stellar Stock For This Coronavirus Bear MarketMadrigal: A Stellar Stock For This Coronavirus Bear Market
seekingalpha.com - April 7 at 3:20 PM
Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 26 at 8:16 AM
Doubling Down On Madrigal PharmaceuticalsDoubling Down On Madrigal Pharmaceuticals
seekingalpha.com - February 5 at 1:10 AM
Why Madrigal Pharma Stock Could Still Double From NASH DevelopmentWhy Madrigal Pharma Stock Could Still Double From NASH Development
247wallst.com - January 30 at 12:12 PM
Madrigal Pharmaceuticals, Inc. (MDGL): Hedge Fund Sentiment UnchangedMadrigal Pharmaceuticals, Inc. (MDGL): Hedge Fund Sentiment Unchanged
finance.yahoo.com - December 19 at 10:56 PM
Dosing underway in Madrigals late-stage resmetirom studyDosing underway in Madrigal's late-stage resmetirom study
seekingalpha.com - December 18 at 8:55 AM
Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))
finance.yahoo.com - December 18 at 8:55 AM
Madrigal Pharmaceuticals investor selling large chunk of its stakeMadrigal Pharmaceuticals investor selling large chunk of its stake
finance.yahoo.com - December 13 at 8:36 AM
Notable Two Hundred Day Moving Average Cross - MDGLNotable Two Hundred Day Moving Average Cross - MDGL
www.nasdaq.com - December 11 at 1:14 PM
Madrigal Pharmaceuticals prices 1.2M-share offeringMadrigal Pharmaceuticals prices 1.2M-share offering
seekingalpha.com - December 11 at 8:14 AM
Madrigal Pharmaceuticals Announces Pricing of Secondary OfferingMadrigal Pharmaceuticals Announces Pricing of Secondary Offering
finance.yahoo.com - December 11 at 12:27 AM
Madrigal launches 1.2M-share stock offering by current investorMadrigal launches 1.2M-share stock offering by current investor
seekingalpha.com - December 10 at 7:27 PM
Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common StockMadrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock
www.marketwatch.com - December 10 at 7:27 PM
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.